Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma

Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study

(2013) Jun Guo et al.   BMC CANCER

Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients With Clear Cell Renal Cell Carcinoma

(2013) Oussama M. Darwish et al.   UROLOGY

Sunitinib and other targeted therapies for renal cell carcinoma

(2011) T Powles et al.   BRITISH JOURNAL OF CANCER

Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases

(2011) B. W. Konicek et al.   CANCER RESEARCH

Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

(2011) Y. Kong et al.   CLINICAL CANCER RESEARCH

Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer

(2011) Jae Hong No et al.   GYNECOLOGIC ONCOLOGY

Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder

(2011) Chih-Hao Sun et al.   HISTOPATHOLOGY

S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer

(2011) Roman Nawroth et al.   PLoS One

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

mTOR signaling and drug development in cancer

(2010) Janet Dancey   Nature Reviews Clinical Oncology

eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression

(2010) L. Furic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin

(2009) S. Assouline et al.   BLOOD

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

(2009) Robert J. Amato et al.   CANCER

eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival

(2009) J. R. Graff et al.   CANCER RESEARCH

Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non-Small Cell Lung Cancer

(2009) A. Yoshizawa et al.   CLINICAL CANCER RESEARCH

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET